Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
Novo Nordisk sues unauthorized semaglutide compounders, tempers expectations for Wegovy’s global rollout
Novo Nordisk is striking back against illegal semaglutide compounders, filing an initial five lawsuits and preparing more in the coming days and weeks. The first